ClinicalTrials.Veeva

Menu

Sequential Oxygen Therapy Strategy for Patients With COVID-19 (SOTSPC)

Z

Zhengzhou University

Status

Unknown

Conditions

Coronavirus Disease-2019

Treatments

Other: oxygen treatment

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

All patients with COVID-19 were divided into three groups according to their illness: mild patient who receive conventional oxygen therapy, severe patients who receive nasal high flow oxygen inhalation or non-invasive positive pressure ventilation,all the oxygen therapy will be used as part of the standard of care. Each group will enroll 10 patients, the treatment of all patients will be continuously optimized during observation, and the incidence of respiratory failure, intubation rate, 28 day mortality rate, ICU hospitalization days, etc will be recorded and analyzed so to optimize the treatment time window of sequential oxygen therapy

Enrollment

30 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients diagnosed with COVID-19

    • Aged between 18-75 years;

      • Willing to sign the informed consent voluntarily.

Exclusion criteria

  • Patients with active tuberculosis, idiopathic pulmonary fibrosis, bronchial asthma, bronchiectasis, pulmonary embolism, chronic respiratory failure or other serious respiratory diseases; ② patients with serious cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina, acute myocardial infarction, cardiac function grade 3 or above, stroke, cerebral hemorrhage, etc.); ③ Patients with serious hepatorenal diseases (serious liver diseases refer to cirrhosis, portal hypertension and varicose bleeding, and serious kidney diseases include dialysis and kidney transplantation); ④ tumor patients who have undergone resection, radiotherapy and chemotherapy within 5 years; ⑤ patients who have difficulty in activity due to neuromuscular diseases; ⑥ patients with serious arthritis; ⑦ patients with serious peripheral vascular diseases; ⑧ Pregnant and lactating women; ⑨ with severe cognitive and mental disorders; ⑩ the clinical researchers who were participating in other interventions within one month before selection;

Trial design

30 participants in 3 patient groups

Mild cases with conventional oxygen therapy
Description:
COVID-19 patients who were considered mild cases will receive conventional oxygen therapy in addition to standard treatment
Treatment:
Other: oxygen treatment
Moderate/Severe cases with nasal high flow oxygen inhalation
Description:
COVID-19 patients who were considered Moderate/Severe cases will receive nasal high flow oxygen inhalation in addition to standard treatment
Treatment:
Other: oxygen treatment
Moderate/Severe cases with non-invasive ventilation
Description:
COVID-19 patients who were considered Moderate/Severe cases will receive non-invasive positive pressure ventilation in addition to standard treatment
Treatment:
Other: oxygen treatment

Trial contacts and locations

1

Loading...

Central trial contact

Ziqi Wang, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems